{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:02:01Z","timestamp":1791234121003,"version":"4.1.0"},"reference-count":49,"publisher":"American Association for Cancer Research (AACR)","issue":"12","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,6,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>New therapies for chronic lymphocytic leukemia (CLL) are needed, particularly those that can eradicate residual disease and elicit anti-CLL immune responses. CD40 ligation on CLL cells, which can be achieved using adenovirus encoding chimeric CD154 (Ad-ISF35), enhances their ability to function as antigen-presenting cells and increases their sensitivity to clearance by immune-effector mechanisms. In this study, we report the results of a first-in-man phase I trial of intranodal direct injection (IDI) of Ad-ISF35 in patients with CLL to evaluate toxicity, safety, and tolerability. Fifteen patients received a single IDI of 1 \u00d7 1010 to 33 \u00d7 1010 Ad-ISF35 viral particles (vp), with a defined maximum tolerated dose as 1 \u00d7 1011 vp. Although the most common adverse events were transient grade 1 to 2 pain at the injection site and flu-like symptoms following IDI, some patients receiving the highest dose had transient, asymptomatic grade 3 to 4 hypophosphatemia, neutropenia, or transaminitis. Increased expression of death receptor, immune costimulatory molecules, and Ad-ISF35 vector DNA was detected in circulating CLL cells. Notably, we also observed preliminary clinical responses, including reductions in leukemia cell counts, lymphadenopathy, and splenomegaly. Six patients did not require additional therapy for more than 6 months, and three achieved a partial remission. In conclusion, Ad-ISF35 IDI was safely delivered in patients with CLLs and induced systemic biologic and clinical responses. These results provide the rationale for phase II studies in CLLs, lymphomas, and CD40-expressing solid tumors. Cancer Res; 72(12); 2937\u201348. \u00a92012 AACR.<\/jats:p>","DOI":"10.1158\/0008-5472.can-11-3368","type":"journal-article","created":{"date-parts":[[2012,4,14]],"date-time":"2012-04-14T01:00:54Z","timestamp":1334365254000},"page":"2937-2948","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Gene Immunotherapy of Chronic Lymphocytic Leukemia: A Phase I Study of Intranodally Injected Adenovirus Expressing a Chimeric CD154 Molecule"],"prefix":"10.1158","volume":"72","author":[{"given":"Januario E.","family":"Castro","sequence":"first","affiliation":[{"name":"Authors' Affiliations:\u20081University of California San Diego Moores Cancer Center; 2Chronic Lymphocytic Leukaemia Research Consortium; and 3Department of Radiology, Interventional Radiology, University of California San Diego, La Jolla, California"},{"name":"Authors' Affiliations:\u20081University of California San Diego Moores Cancer Center; 2Chronic Lymphocytic Leukaemia Research Consortium; and 3Department of Radiology, Interventional Radiology, University of California San Diego, La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Melo-Cardenas","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081University of California San Diego Moores Cancer Center; 2Chronic Lymphocytic Leukaemia Research Consortium; and 3Department of Radiology, Interventional Radiology, University of California San Diego, La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio","family":"Urquiza","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081University of California San Diego Moores Cancer Center; 2Chronic Lymphocytic Leukaemia Research Consortium; and 3Department of Radiology, Interventional Radiology, University of California San Diego, La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan S.","family":"Barajas-Gamboa","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081University of California San Diego Moores Cancer Center; 2Chronic Lymphocytic Leukaemia Research Consortium; and 3Department of Radiology, Interventional Radiology, University of California San Diego, La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin S.","family":"Pakbaz","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081University of California San Diego Moores Cancer Center; 2Chronic Lymphocytic Leukaemia Research Consortium; and 3Department of Radiology, Interventional Radiology, University of California San Diego, La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Kipps","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081University of California San Diego Moores Cancer Center; 2Chronic Lymphocytic Leukaemia Research Consortium; and 3Department of Radiology, Interventional Radiology, University of California San Diego, La Jolla, California"},{"name":"Authors' Affiliations:\u20081University of California San Diego Moores Cancer Center; 2Chronic Lymphocytic Leukaemia Research Consortium; and 3Department of Radiology, Interventional Radiology, University of California San Diego, La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2012,6,14]]},"reference":[{"key":"2022061703505732600_bib1","first-page":"1431","article-title":"Chronic lymphocytic leukemia and related diseases","volume-title":"Williams hematology","author":"Kipps","year":"2010","edition":"8th ed"},{"key":"2022061703505732600_bib2","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2008-02-140582","article-title":"Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"key":"2022061703505732600_bib3","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"2022061703505732600_bib4","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/leu.2010.89","article-title":"Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy","volume":"24","author":"Ysebaert","year":"2010","journal-title":"Leukemia"},{"key":"2022061703505732600_bib5","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1182\/blood-2009-07-233718","article-title":"Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance","volume":"114","author":"Kurtova","year":"2009","journal-title":"Blood"},{"key":"2022061703505732600_bib6","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/bjc.1990.79","article-title":"The roles of lymph node stromal cells in proliferation of lymphoid leukaemia cells","volume":"61","author":"Tsuda","year":"1990","journal-title":"Br J Cancer"},{"key":"2022061703505732600_bib7","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1182\/blood.V100.5.1795.h81702001795_1795_1801","article-title":"Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1","volume":"100","author":"Pedersen","year":"2002","journal-title":"Blood"},{"key":"2022061703505732600_bib8","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1158\/1078-0432.CCR-07-2223","article-title":"The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance","volume":"14","author":"Meads","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2022061703505732600_bib9","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1182\/blood-2010-05-284984","article-title":"The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia","volume":"117","author":"Herishanu","year":"2011","journal-title":"Blood"},{"key":"2022061703505732600_bib10","first-page":"104","article-title":"Immunogenetic therapy for B-cell malignancies","volume":"27","author":"Kipps","year":"2000","journal-title":"Semin Oncol"},{"key":"2022061703505732600_bib11","first-page":"2427","article-title":"Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug","volume":"118","author":"Ramsay","year":"2008","journal-title":"J Clin Invest"},{"key":"2022061703505732600_bib12","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1053\/j.seminoncol.2010.09.002","article-title":"Biology and clinical applications of CD40 in cancer treatment","volume":"37","author":"Fonsatti","year":"2010","journal-title":"Semin Oncol"},{"key":"2022061703505732600_bib13","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1182\/blood-2007-04-084756","article-title":"The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells","volume":"112","author":"Luqman","year":"2008","journal-title":"Blood"},{"key":"2022061703505732600_bib14","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1200\/JCO.2006.08.3311","article-title":"Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody","volume":"25","author":"Vonderheide","year":"2007","journal-title":"J Clin Oncol"},{"key":"2022061703505732600_bib15","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1200\/JCO.2001.19.13.3280","article-title":"Phase I study of recombinant human CD40 ligand in cancer patients","volume":"19","author":"Vonderheide","year":"2001","journal-title":"J Clin Oncol"},{"key":"2022061703505732600_bib16","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.it.2011.02.004","article-title":"Innate control of B cell responses","volume":"32","author":"Cerutti","year":"2011","journal-title":"Trends Immunol"},{"key":"2022061703505732600_bib17","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1084\/jem.177.4.925","article-title":"Activated T cells induce expression of B7\/BB1 on normal or leukemic B cells through a CD40-dependent signal","volume":"177","author":"Ranheim","year":"1993","journal-title":"J Exp Med"},{"key":"2022061703505732600_bib18","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1182\/blood.V93.6.1992.406k23_1992_2002","article-title":"CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells","volume":"93","author":"Buhmann","year":"1999","journal-title":"Blood"},{"key":"2022061703505732600_bib19","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1172\/JCI1472","article-title":"Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells","volume":"101","author":"Kato","year":"1998","journal-title":"J Clin Invest"},{"key":"2022061703505732600_bib20","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1182\/blood-2003-10-3684","article-title":"Fas-ligand (CD178) and TRAIL synergistically induce apoptosis of CD40-activated chronic lymphocytic leukemia B cells","volume":"105","author":"Dicker","year":"2005","journal-title":"Blood"},{"key":"2022061703505732600_bib21","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1073\/pnas.0712148105","article-title":"Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a","volume":"105","author":"Fukuda","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061703505732600_bib22","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1182\/blood.V96.9.2917","article-title":"CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia","volume":"96","author":"Wierda","year":"2000","journal-title":"Blood"},{"key":"2022061703505732600_bib23","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1038\/leu.2010.191","article-title":"A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154","volume":"24","author":"Wierda","year":"2010","journal-title":"Leukemia"},{"key":"2022061703505732600_bib24","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1182\/blood.V116.21.1470.1470","article-title":"Ad-ISF35 intratumoral administration induces a bystander effect and immune-mediated tumor rejection with a safe vector biodistribution and toxicology profile in a NHL mouse model","volume":"116","author":"Melo-Cardenas","year":"2010","journal-title":"Blood"},{"key":"2022061703505732600_bib25","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/cgt.2012.6","article-title":"Intratumoral delivery of CD154 homolog (Ad-ISF35) induces tumor regression: analysis of vector biodistribution, persistence and gene expression","volume":"19","author":"Melo-Cardenas","year":"2012","journal-title":"Cancer Gene Ther"},{"key":"2022061703505732600_bib26","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990","article-title":"National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment","volume":"87","author":"Cheson","year":"1996","journal-title":"Blood"},{"key":"2022061703505732600_bib27","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"2022061703505732600_bib28","author":"National Institutes of Health-clinicaltrials.gov"},{"key":"2022061703505732600_bib29","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa040857","article-title":"ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia","volume":"351","author":"Rassenti","year":"2004","journal-title":"N Engl J Med"},{"key":"2022061703505732600_bib30","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/sj.cgt.7700568","article-title":"A phase I trial of immunotherapy with intratumoral adenovirus-interferon-gamma (TG1041) in patients with malignant melanoma","volume":"10","author":"Khorana","year":"2003","journal-title":"Cancer Gene Ther"},{"key":"2022061703505732600_bib31","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/gt.2008.179","article-title":"A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients","volume":"16","author":"Li","year":"2009","journal-title":"Gene Ther"},{"key":"2022061703505732600_bib32","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1200\/JCO.2005.00.463","article-title":"Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas","volume":"23","author":"Mazzolini","year":"2005","journal-title":"J Clin Oncol"},{"key":"2022061703505732600_bib33","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0002-9343(97)00275-1","article-title":"Prevalence of hypophosphatemia in sepsis and infection: the role of cytokines","volume":"104","author":"Barak","year":"1998","journal-title":"Am J Med"},{"key":"2022061703505732600_bib34","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/SHK.0b013e318180feb8","article-title":"Comparison of the effects of aging and IL-6 on the hepatic inflammatory response in two models of systemic injury: scald injury versus i.p. LPS administration","volume":"31","author":"Gomez","year":"2009","journal-title":"Shock"},{"key":"2022061703505732600_bib35","first-page":"502","article-title":"Gene therapy of hematologic malignancies","volume":"27","author":"Wierda","year":"2000","journal-title":"Semin Oncol"},{"key":"2022061703505732600_bib36","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0145-2126(99)00045-4","article-title":"Autoimmune disease induced by dendritic cell immunization against leukemia","volume":"23","author":"Roskrow","year":"1999","journal-title":"Leuk Res"},{"key":"2022061703505732600_bib37","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000142050","article-title":"Severe congenital neutropenia or hyper-IgM syndrome? A novel mutation of CD40 ligand in a patient with severe neutropenia","volume":"147","author":"Rezaei","year":"2008","journal-title":"Int Arch Allergy Immunol"},{"key":"2022061703505732600_bib38","first-page":"37","article-title":"Successful management of neutropenia in a patient with CD40 ligand deficiency by immunoglobulin replacement therapy","volume":"6","author":"Atarod","year":"2007","journal-title":"Iran J Allergy Asthma Immunol"},{"key":"2022061703505732600_bib39","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1136\/adc.74.5.458","article-title":"CD40 ligand deficiency presenting as unresponsive neutropenia","volume":"74","author":"Andrews","year":"1996","journal-title":"Arch Dis Child"},{"key":"2022061703505732600_bib40","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1080\/10428190802258956","article-title":"Evaluation of procalcitonin, neopterin, C-reactive protein, IL-6 and IL-8 as a diagnostic marker of infection in patients with febrile neutropenia","volume":"49","author":"Prat","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"2022061703505732600_bib41","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1385\/MO:18:1:51","article-title":"Serum levels of IL-1 beta, sIL-2R, IL-6, IL-8, and TNF-alpha in febrile children with cancer and neutropenia","volume":"18","author":"Soker","year":"2001","journal-title":"Med Oncol"},{"key":"2022061703505732600_bib42","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1038\/sj.gt.3301796","article-title":"Adenoviral transduction of tumor cells induces apoptosis in co-cultured T lymphocytes","volume":"9","author":"Scholz","year":"2002","journal-title":"Gene Therapy"},{"key":"2022061703505732600_bib43","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1126\/science.1198443","article-title":"CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans","volume":"331","author":"Beatty","year":"2011","journal-title":"Science"},{"key":"2022061703505732600_bib44","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1002\/art.10273","article-title":"The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus","volume":"46","author":"Huang","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2022061703505732600_bib45","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/art.10856","article-title":"A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis","volume":"48","author":"Boumpas","year":"2003","journal-title":"Arthritis Rheum"},{"key":"2022061703505732600_bib46","first-page":"1902","article-title":"Improved vaccination response during ranitidine treatment, and increased plasma histamine concentrations, in patients with B cell chronic lymphocytic leukemia","volume":"9","author":"Jurlander","year":"1995","journal-title":"Leukemia"},{"key":"2022061703505732600_bib47","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1200\/JCO.2005.04.021","article-title":"Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival","volume":"23","author":"Moreton","year":"2005","journal-title":"J Clin Oncol"},{"key":"2022061703505732600_bib48","doi-asserted-by":"crossref","first-page":"31a","DOI":"10.1182\/blood.V116.21.55.55","article-title":"CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110 delta, demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemia","volume":"116","author":"Furman","year":"2010","journal-title":"Blood"},{"key":"2022061703505732600_bib49","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/blood.V116.21.57.57","article-title":"The Bruton's tyrosine kinase inhibitor, PCI-32765, is well tolerated and demonstrates promising clinical activity in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): an update on ongoing phase 1 studies","volume":"116","author":"Burger","year":"2010","journal-title":"Blood"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/72\/12\/2937\/2669832\/2937.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/72\/12\/2937\/2669832\/2937.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T08:56:29Z","timestamp":1655456189000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/72\/12\/2937\/575824\/Gene-Immunotherapy-of-Chronic-Lymphocytic-Leukemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,14]]},"references-count":49,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2012,6,14]]},"published-print":{"date-parts":[[2012,6,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-11-3368","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.22392345","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6503502.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6503502","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22392345.v1","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,14]]}}}